Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
A 2021 pharmacokinetic study published in Clinical Pharmacokinetics (Urva et al.) measured tirzepatide levels in 89 healthy volunteers receiving weekly doses ranging from 0.5 mg to 15 mg
Insurance coverage varies
Inadequate calories, calcium, vitamin D, and other micronutrients can also compromise bone density
PMID: 21782840
Composition CJC-1295 (Without DAC): 5 mg Ipamorelin: 5 mg Appearance: Lyophilized powder in a sealed research vial Research Focus (non-clinical) Comparative and combined pathway evaluation of GHRH analog + GHS agonist in in-vitro or ex-vivo models Assessment of assay development, including chromatographic separation of co-formulated peptides Stability characterization of a two-analyte lyophilized blend under laboratory storage conditions Documentation Lot-specific COA available Batch and lot traceability Important Notice For research use only Not for human consumption Not intended to diagnose, treat, cure, or prevent any disease Quality & Manufacturing Lot-specific COA Lyophilized for transit stability
US$ 28.52
US$ 22.02
US$ 21.34
US$ 29.67
US$ 22.80
US$ 26.94
US$ 28.24
